Financial Performance - The company's revenue for Q1 2024 was ¥115,797,089.07, representing an increase of 8.27% compared to ¥106,949,889.42 in the same period last year[5] - Net profit attributable to shareholders was ¥33,384,770.13, a significant increase of 33.55% from ¥24,997,456.97 year-on-year[5] - Operating profit for the quarter was ¥39,098,898.50, representing a growth of 35.0% from ¥28,981,024.75 in Q1 2023[19] - Total operating revenue for Q1 2024 reached ¥115,797,089.07, an increase of 7.3% compared to ¥106,949,889.42 in Q1 2023[18] - Net profit attributable to the parent company was ¥33,384,770.13, up 33.4% from ¥24,997,456.97 in the same period last year[19] Cash Flow and Liquidity - The net cash flow from operating activities surged by 557.07% to ¥21,581,743.55, compared to ¥3,284,551.58 in the previous year[5] - Cash flow from operating activities generated ¥21,581,743.55, significantly higher than ¥3,284,551.58 in Q1 2023[20] - The company reported a net increase in cash and cash equivalents of ¥8,027,047.49, contrasting with a decrease of ¥5,427,797.87 in the previous year[21] - The company's cash and cash equivalents reached CNY 951,780,526.11, up from CNY 943,753,478.62, indicating a slight increase of about 0.1%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,355,809,158.15, reflecting a growth of 1.11% from ¥1,340,950,789.82 at the end of the previous year[5] - The total assets of Zhejiang Haishen Pharmaceutical Co., Ltd. as of March 31, 2024, amounted to CNY 1,355,809,158.15, an increase from CNY 1,340,950,789.82 at the beginning of the period, reflecting a growth of approximately 1.3%[16] - Total current liabilities decreased from CNY 78,774,115.26 to CNY 52,034,027.44, a decline of approximately 33.4%[17] - The company reported a significant decrease in accounts payable from CNY 32,624,235.59 to CNY 20,022,204.26, a reduction of about 38.8%[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,256, with the largest shareholder holding 32.96% of the shares[12] - The company has a total of 68,000,000 shares outstanding, with no changes in the share capital during the period[17] - The total equity attributable to shareholders reached ¥1,283,090,209.51, up from ¥1,249,334,654.85 in Q1 2023[18] - The company's total equity increased to CNY 408,770,621.27 from CNY 375,385,851.14, reflecting a growth of about 8.9%[17] Research and Development - Research and development expenses rose by 42.58% to ¥4,279,248.99, primarily due to increased salaries for R&D personnel and depreciation of experimental instruments[10] - Research and development expenses increased to ¥4,279,248.99, a rise of 42.6% compared to ¥3,001,211.35 in the previous year[18] Financial Ratios and Performance Metrics - The weighted average return on net assets decreased to 2.64%, down by 2.55% from 5.19% in the previous year[5] - The company reported a significant increase in accounts receivable financing, which rose by 792.95% to ¥30,475,027.89, attributed to the predominant use of bills for settlement with major clients[10] - The company experienced a foreign exchange gain of ¥983,294.37, compared to a loss of ¥189,281.76 in Q1 2023[21] - The company's retained earnings increased by CNY 33,384,770.13 during the quarter, reflecting positive operational performance[17]
海森药业(001367) - 2024 Q1 - 季度财报